Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
暂无分享,去创建一个
E. Tartour | S. Wain-Hobson | C. Borg | C. Sedlik | Y. Godet | Y. Lone | P. Langlade‐Demoyen | O. Adotévi | F. Sandoval | É. Daguindau | C. Liard | M. Dosset | Laurent Beziaud | C. Vauchy | E. Levionnois | Bertrand Clerc | Federico Sandoval
[1] E. Tartour,et al. Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response , 2012, Clinical Cancer Research.
[2] V. Georgoulias,et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[4] S. Aamdal,et al. Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial , 2011, Clinical Cancer Research.
[5] S. Quezada,et al. Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities. , 2011, Immunotherapy.
[6] M. Ross,et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Marincola,et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.
[8] S. Aamdal,et al. Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients , 2011, Clinical Cancer Research.
[9] N. Yawalkar,et al. Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. , 2011, Journal of dermatological science.
[10] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[11] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[12] J. Galon,et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.
[13] L. Sherman,et al. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.
[14] S. Wain-Hobson,et al. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice. , 2010, Vaccine.
[15] Y. Takeda,et al. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. , 2010, Anticancer research.
[16] E. Tartour,et al. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. , 2010, Blood.
[17] W. Paul,et al. Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.
[18] B. Saha,et al. Protumor vs Antitumor Functions of IL-171 , 2009, The Journal of Immunology.
[19] J. Sidney,et al. High-avidity Autoreactive CD4+ T Cells Induce Host CTL, Overcome Tregs and Mediate Tumor Destruction , 2009, Journal of immunotherapy.
[20] R. Vonderheide,et al. Telomerase as a universal tumor antigen for cancer vaccines , 2008, Expert review of vaccines.
[21] W. Paul,et al. CD4 T cells: fates, functions, and faults. , 2008, Blood.
[22] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[23] E. Celis,et al. Peptide epitope identification for tumor-reactive CD4 T cells. , 2008, Current opinion in immunology.
[24] R. Kennedy,et al. Multiple roles for CD4+ T cells in anti‐tumor immune responses , 2008, Immunological reviews.
[25] C. Harley,et al. Telomerase and cancer therapeutics , 2008, Nature Reviews Cancer.
[26] L. Sherman,et al. Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells1 , 2008, The Journal of Immunology.
[27] D. Mavroudis,et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[29] A. Tyznik,et al. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.
[30] E. Tartour,et al. Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses , 2006, Clinical Cancer Research.
[31] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[32] K. Knutson,et al. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[33] A. Pajot,et al. A mouse model of human adaptive immune functions: HLA‐A2.1‐/HLA‐DR1‐transgenic H‐2 class I‐/class II‐knockout mice , 2004, European journal of immunology.
[34] Gabrielle T Belz,et al. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity , 2004, Nature Immunology.
[35] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[36] B. Rocha,et al. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. , 2004, Current opinion in immunology.
[37] P. Opolon,et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. , 2004, The Journal of clinical investigation.
[38] C. Rooney,et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] Hao Shen,et al. Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.
[40] Javier Hernández,et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[41] F. Lemonnier,et al. HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy1 , 2002, The Journal of Immunology.
[42] Jingwu Z. Zhang,et al. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. , 2002, Cancer research.
[43] B. Robinson,et al. Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1 , 2000, The Journal of Immunology.
[44] T. Blankenstein,et al. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.
[45] A. Ohta,et al. Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.
[46] D. Pardoll,et al. The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.
[47] Richard A. Flavell,et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.
[48] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[49] R. Reddel. Telomerase and cancer. , 1997, Japanese journal of cancer research : Gann.
[50] C. Leclerc,et al. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. , 1991, Journal of immunology.
[51] R. DePinho,et al. Telomeres and telomerase in cancer. , 2010, Carcinogenesis.